Press Release Summary:
Designed to help improve paper quality as well as economics of pulp and paper manufacturing processes, FIBREZYMEÂ® G200 enhances and restores fiber strength in addition to increasing inter-fiber bonding through fibrillation. Product can also help improve softness in tissue production as well as pulp drainage rates while reducing paper drying demand. Product can also help reduce fiber raw material requirements, petroleum-derived chemical use, and pulp refining energy requirements.
Original Press Release:
Dyadic International Launches High Performance Enzyme for Pulp and Paper Industry Using New C1 Production Platform
FIBREZYME® G200 reduces production costs while also improving fiber-to-fiber bonding and pulp refining properties
JUPITER, Fla. -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries, announced today that it has launched FibreZyme® G200, a next generation, high performance enzyme designed to improve paper quality and improve the economics of various pulp and paper manufacturing processes.
Brian Murdoch, Dyadic's Senior Director Sales & Technical Development stated, "FibreZyme® G200 is a great addition to our product portfolio and provides further evidence of the value-adding capabilities of Dyadic's C1 platform technology. FibreZyme® G200 operates under wide pH and temperature ranges allowing for seamless integration into most pulp and paper manufacturing processes."
Specific attributes of FibreZyme® G200 include the following:
New Production Platform
FibreZyme® G200 is produced using a new variant of Dyadic's patented and proprietary C1 platform technology which Dyadic refers to as the "white strain." Developed through sustained research efforts at Dyadic Netherlands, the white strain produces significantly less background proteins. These changes allow for more efficient and economical industrial scale production of highly targeted enzymes and proteins at greater purity levels.
Richard Jundzil, Dyadic's Vice President Operations stated, "FibreZyme® G200 represents the first product commercialized using the new C1 white strain. We now have in place all the molecular tools, scale-up experience and production processes necessary to support additional timely market introductions of new enzymes identified from the C1 and other genomes. Dyadic intends to utilize the white strain production platform to create a sustainable and more diverse product portfolio. We also intend to express new enzyme and protein targets with our collaborative partners in a variety of industries."
Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries. Please visit Dyadic's website at www.dyadic.com and Dyadic Netherland's website at www.dyadic.nl.
For more information about FibreZyme® G200, please visit www.FibreZyme.com.
CONTACT: Thomas M. O'Shaughnessy, Vice President Sales & Marketing, Dyadic International, Inc., +1-561-743-8333, email@example.com